Identifying Regulators of Antibody–drug Conjugate Toxicity
Antibody–drug conjugates or ADCs selectively deliver a a cytotoxic payload to target cancer cells, making them important anti-cancer therapeutics....
Using a Hydrophilic Spacer to Reduce Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates
In the development of novel drug conjugates alternatives to monoclonal antibodies (mAbs) have started to emerge. While antibodies have...
Using Middle-Down Mass Spectrometry to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate
Antibody–drug conjugates are among the fastest growing classes of anti-cancer
therapeutics.With the 5 approved and commercially available agents, and nearly...
A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing Antibody to a...
The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make...
Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in...
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC...
Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer
Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2...
A Review of Cleavable Linkers
With 5 commercially available antibody-drug conjugates (ADCs) an nearly 100 novel agents in developments - from early discovery to...
New Reagents for the Rapid Generation of Efficacious Antibody-drug Conjugates
Because conjugation selectivity as well as stability and hydrophobicity of linkers and payloads drastically influence the performance and safety...
Anti-CD205 Antibody-Drug Conjugate MEN1309/OBT076 Shows Substantial in vitro Antitumor Activity
Non-clinical study findings published in the journal Molecular Cancer Therapeutics describing the characterization of the anti-CD205 antibody-drug conjugate (ADC)...
New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers
Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called...
